Bortezomib-induced aerobic glycolysis contributes to chemotherapy-induced painful peripheral neuropathy.

Crucially, the data reveal that targeted inhibition of the enzymes that maintain aerobic glycolysis can serve as a valid strategy for treating CIPN—a highly significant clinical challenge.

also in 132,142 other papers